KalVista Pharmaceuticals, Inc.
Financial highlights
| Metric | FY 04/30/25 | FY 04/30/24 | FY 04/30/23 | FY 04/30/22 | FY 04/30/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | $50.0M | — | — | — |
| Research and development | $71.7M | $86.2M | $80.3M | $70.2M | $41.3M |
| Operating expenses | $188.0M | $140.4M | $110.9M | $96.6M | $57.9M |
| Operating income | -$188.0M | -$140.4M | -$110.9M | -$96.6M | -$57.9M |
| Interest expense | $5.8M | — | — | — | — |
| Pretax income | -$180.1M | -$126.6M | -$92.9M | -$82.3M | -$46.2M |
| Income tax expense | $3.4M | $0 | $0 | $0 | $0 |
| Net income | -$183.4M | -$126.6M | -$92.9M | -$82.3M | -$46.2M |
| Balance Sheet | |||||
| Cash and equivalents | $131.6M | $31.8M | $56.2M | $30.7M | $50.6M |
| Current assets | $241.7M | $225.7M | $172.3M | $193.6M | $264.3M |
| Total assets | $250.8M | $235.4M | $183.2M | $203.9M | $272.0M |
| Current liabilities | $45.2M | $22.8M | $15.0M | $11.6M | $9.8M |
| Stockholders' equity | $95.4M | $206.6M | $161.0M | $185.1M | $257.2M |
| Cash Flow Statement | |||||
| Cash from operations | -$152.9M | -$89.2M | -$75.3M | -$78.1M | -$30.2M |
| Depreciation and amortization | $941,000 | $816,000 | $718,000 | $564,000 | $537,000 |
| Stock-based compensation | $12.3M | $21.9M | $9.9M | $11.1M | $7.1M |
| Capital expenditure | $434,000 | $42,000 | $1.2M | $931,000 | $82,000 |
| Free cash flow | -$153.3M | -$89.3M | -$76.5M | -$79.1M | -$30.3M |
Shares outstanding 53.2M · Free float 38.0%
Annual filing data through FY ended April 30, 2025; float as of July 13, 2026.